DiaMedica Therapeutics (NASDAQ:DMAC) Upgraded by Zacks Investment Research to Buy

DiaMedica Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  DiaMedica Therapeutics Upgraded by Zacks Investment Research on 10/12/2021. In a note to investors, the firm issued a new rating of Buy. The analysts previously had rating of Hold.

View More DiaMedica Therapeutics (NASDAQ:DMAC) Upgraded by Zacks Investment Research to Buy